Physician profile
Christopher E Acker
NPI 1497100564
$3,442.44
in general payments reported to CMS, 2019-2025
33 companies · $919 in 2025
The $919 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $521 · 2022: $539 · 2023: $621 · 2024: $843 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,364 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,363.58 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,023.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $366.53 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $321.28 | 2021-2025 | |
| Amgen INC. | $299.39 | 2023-2025 | Repatha, Repatha, Otezla |
| Glaxosmithkline, LLC. | $257.38 | 2021-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $232.56 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Jazz Pharmaceuticals INC. | $97.69 | 2021-2022 | |
| Lundbeck LLC | $92.30 | 2021-2023 | Vyepti |
| Astellas Pharma US INC | $69.22 | 2023-2025 | Veozah |
| Inspire Medical Systems, INC. | $65.93 | 2023 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.16 | 2021-2025 | Jardiance |
| Tris Pharma INC | $48.06 | 2023-2025 | Dyanavel Xr |
| Vbi Vaccine (Delaware) INC. | $44.09 | 2022 | |
| Sanofi-Aventis U.S. LLC | $41.14 | 2024-2025 | |
| Nevro Corp. | $34.90 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $31.82 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Dynavax Technologies Corporation | $30.84 | 2024-2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $30.10 | 2024-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Boston Scientific Corporation | $27.87 | 2024 | |
| Exact Sciences Corporation | $27.29 | 2024 | Cologuard Collection Kit |
| Dexcom, INC. | $25.83 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $25.66 | 2021-2022 | |
| Abbott Laboratories | $21.99 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $18.86 | 2025 | Neffy |
| Daiichi Sankyo INC. | $18.23 | 2024 | Injectafer |
| Xeris Pharmaceuticals, INC. | $17.48 | 2025 | Gvoke Hypopen |
| Seqirus USA INC | $17.47 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.85 | 2023 | Quviviq |
| Baxter Healthcare | $14.99 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic, INC. | $14.51 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.